Pancuronium Bromide — Veterinary Vademecum Drug Reference

Dosage & Administration Guidelines

Species	Route	Dose	Frequency	Duration & Clinical Notes
Dog	IV	0.05-0.1 mg/kg	Initial dose; maintenance: 0.01-0.02 mg/kg every 20-40 minutes as needed	Duration: As needed during anesthesia Notes: Administer only when adequate anesthesia and ventilatory support are available. Use lower end of dose range in debilitated animals.
Cat	IV	0.05-0.1 mg/kg	Initial dose; maintenance: 0.01-0.02 mg/kg every 20-40 minutes as needed	Duration: As needed during anesthesia Notes: Cats may be more sensitive; monitor heart rate and blood pressure.
Horse	IV	0.05-0.1 mg/kg	Initial dose; maintenance: 0.01-0.02 mg/kg every 30-60 minutes as needed	Duration: As needed during anesthesia Notes: Ensure adequate ventilation; pancuronium may cause tachycardia.
Cattle	IV	0.05-0.1 mg/kg	Initial dose; maintenance: 0.01-0.02 mg/kg every 30-60 minutes as needed	Duration: As needed during anesthesia Notes: Use with caution in ruminants due to risk of regurgitation and bloat.
Small Ruminants (sheep, goats)	IV	0.05-0.1 mg/kg	Initial dose; maintenance: 0.01-0.02 mg/kg every 30-60 minutes as needed	Duration: As needed during anesthesia Notes: Monitor for respiratory depression; have reversal agents ready.
Rabbit	IV	0.05-0.1 mg/kg	Initial dose; maintenance: 0.01-0.02 mg/kg every 20-40 minutes as needed	Duration: As needed during anesthesia Notes: Rabbits are prone to respiratory complications; use with extreme caution.

Clinical Indications & Species Uses

General Indications

Skeletal muscle relaxation during surgery
Facilitation of mechanical ventilation
Reduction of anesthetic requirements

Dog (Canine)

Adjunct to general anesthesia to provide skeletal muscle relaxation
Facilitation of endotracheal intubation
Mechanical ventilation management

Cat (Feline)

Adjunct to general anesthesia to provide skeletal muscle relaxation
Facilitation of endotracheal intubation
Mechanical ventilation management

Horse (Equine)

Adjunct to general anesthesia for muscle relaxation
Facilitation of endotracheal intubation
Ophthalmic surgery requiring akinesia

Cattle (Bovine)

Adjunct to general anesthesia for muscle relaxation
Facilitation of endotracheal intubation

Small Ruminants (Sheep / Goat)

Adjunct to general anesthesia for muscle relaxation
Facilitation of endotracheal intubation

Rabbit & Small Mammals

Adjunct to general anesthesia for muscle relaxation
Facilitation of endotracheal intubation

Exotic & Other Species

Adjunct to anesthesia in some exotic species (e.g., reptiles, primates) with caution

Pharmacology & Mechanism of Action

Drug Class: Neuromuscular Blocking Agent | Pharmacological Group: Non-depolarizing (competitive) neuromuscular blocker

Mechanism of Action: Pancuronium bromide is a synthetic bisquaternary aminosteroid compound that acts as a competitive antagonist at nicotinic acetylcholine receptors at the neuromuscular junction. It binds to the alpha subunits of the postsynaptic nicotinic receptor, preventing acetylcholine from binding and thereby blocking neuromuscular transmission. This results in flaccid paralysis of skeletal muscles. The effect is reversible by acetylcholinesterase inhibitors such as neostigmine, which increase acetylcholine concentration at the junction.

Pharmacodynamics: Pancuronium produces dose-dependent skeletal muscle relaxation. It has a relatively slow onset of action (2-4 minutes) and a long duration of effect (40-60 minutes in dogs and cats). It has minimal cardiovascular effects at clinical doses, but may cause a slight increase in heart rate due to vagolytic activity and release of catecholamines. It does not have significant analgesic or anesthetic properties.

⚡ Pharmacokinetics Summary

Absorption: Not administered orally; only parenteral routes (IV) are used. Absorption is not applicable.

Distribution: Pancuronium is distributed throughout the extracellular fluid. It crosses the placenta but does not cross the blood-brain barrier significantly. Volume of distribution is approximately 0.25 L/kg in dogs.

Metabolism: Partially metabolized in the liver by deacetylation to 3-hydroxy and 17-hydroxy derivatives, which have some neuromuscular blocking activity. Metabolism is limited in most species.

Excretion: Excreted primarily unchanged in the urine (up to 60-80% in humans). Biliary excretion also occurs. In animals with renal impairment, elimination is prolonged.

Half-Life: Dogs: approximately 1-2 hours; Cats: approximately 1-1.5 hours; Horses: approximately 1.5-2 hours.

Bioavailability: Not applicable (IV only).

Protein Binding: Approximately 30% bound to plasma proteins.

Available Formulations & Strengths

Injectable Solution 2 mg/mL (2 mL vials) (IV)

Contraindications & Clinical Warnings

Contraindications:

Known hypersensitivity to pancuronium or other aminosteroid neuromuscular blockers
In patients where tachycardia or increased heart rate is undesirable (e.g., severe cardiac disease)
In patients with myasthenia gravis (unless used with extreme caution and ventilatory support)
In patients with severe electrolyte imbalances (e.g., hypokalemia, hypermagnesemia) that may potentiate blockade

Warnings & Clinical Precautions:

For use only by experienced personnel with facilities for intubation, mechanical ventilation, and reversal agents.
Pancuronium has no analgesic or anesthetic properties; must be used with adequate anesthesia.
Use with caution in patients with hepatic or renal impairment, as elimination may be prolonged.
May cause histamine release (less than other agents) and hypotension in some animals.
Monitor neuromuscular function (e.g., peripheral nerve stimulator) to avoid overdosage.
In food animals, observe withdrawal times; not approved for use in animals intended for food in many countries.
Use in pregnant animals only if clearly needed; crosses placenta.

Adverse Effects & Reactions

Common:

Tachycardia
Slight hypotension or hypertension
Salivation
Bronchospasm (rare)

Serious / Severe:

Prolonged neuromuscular blockade
Respiratory depression or apnea
Cardiac arrhythmias
Anaphylaxis (rare)

Rare:

Malignant hyperthermia (in susceptible species)
Myopathy after prolonged use

Key Drug Interactions

Interacting Drug / Class	Clinical Effect & Mechanism	Severity
Inhalational anesthetics (e.g., isoflurane, sevoflurane)	Potentiate neuromuscular blockade; reduce pancuronium dose by 20-30%.	High
Aminoglycoside antibiotics (e.g., gentamicin, amikacin)	Enhance neuromuscular blockade; increased risk of respiratory depression.	High
Tetracyclines	May potentiate neuromuscular blockade.	Moderate
Magnesium sulfate	Enhances neuromuscular blockade; use with caution.	High
Calcium channel blockers	May prolong neuromuscular blockade.	Moderate
Diuretics (e.g., furosemide)	May cause electrolyte imbalances that alter neuromuscular blockade.	Moderate
Anticholinesterases (e.g., neostigmine)	Antagonize the neuromuscular blockade; used for reversal.	Mild (therapeutic)

Overdose & Toxicity Management

Signs of Toxicity:

Prolonged muscle paralysis
Apnea
Hypotension
Bradycardia or tachycardia
Hypoxemia

Emergency Treatment Protocol: Maintain airway and provide mechanical ventilation until recovery. Administer anticholinesterase (e.g., neostigmine 0.02-0.04 mg/kg IV) preceded by atropine (0.02-0.04 mg/kg IV) to counteract muscarinic effects. Monitor vital signs and provide supportive care. In severe cases, consider plasma cholinesterase administration (not commonly available).

Food Animal Withdrawal Times

Pancuronium is not approved for use in food-producing animals in many jurisdictions. If used in an extra-label manner, a prolonged withdrawal period (e.g., 30 days for meat and 7 days for milk) is recommended, but consult regulatory authorities.

Storage, Handling & Regulatory Information

Storage Temperature: Store at controlled room temperature 20-25°C (68-77°F); protect from freezing.

Handling & Special Conditions: Protect from light; keep in original carton until use. Do not mix with alkaline solutions.

Dispensing Status: Prescription Required (Rx Only)

Approval Status: Not FDA-approved for veterinary use; approved for human use.

Extra-Label (Off-Label) Use: In the US, pancuronium is not FDA-approved for veterinary use; use is extra-label under AMDUCA. Requires a valid veterinarian-client-patient relationship. For food animals, withdrawal times must be established by the veterinarian.

Clinical Pearls & Practice Notes

💡 Clinical Insights: Pancuronium is a valuable adjunct to general anesthesia in veterinary practice, providing excellent muscle relaxation for surgical procedures, especially orthopedic and ophthalmic surgeries. It is essential to have facilities for mechanical ventilation and reversal agents (neostigmine with atropine) readily available. Because of its vagolytic effect, it may cause tachycardia, which can be beneficial in patients with bradycardia but detrimental in those with cardiac disease. Monitoring neuromuscular blockade with a peripheral nerve stimulator is recommended to avoid overdosage. Pancuronium is not a substitute for anesthetics; it must be used with appropriate anesthetic agents. In food animals, its use is highly restricted due to lack of withdrawal data. Always follow institutional protocols and legal regulations.

References & Literature

📚 Plumb's Veterinary Drug Handbook
📚 Papich Veterinary Pharmacology and Therapeutics
📚 Compendium of Veterinary Products (CVP)